[Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
OBJECTIVE
An analysis of changes in plasma levels of MMP-2 and MMP-9 as well as the tissue inhibitors TIMP-1 and TIMP-2 in children diagnosed for acute lymphoblastic leukemia (ALL).


METHODS
In 21 children aged from 1 to 15 with ALL (17 with pre-B ALL and 4 with T-ALL) we made the analysis: at diagnosis (point I), after induction remission (point II) and after the end of intensive treatment (point III). Control group was composed of 47 healthy persons.


RESULTS
At diagnosis, the mean plasma values of MMP-2, MMP-9, TIMP-2 were lower than in control group, whereas TIMP-1 levels were similar. During and after the treatment we found the increase of MMP-2 comparing to the values at diagnosis (relatively p = 0.003 and p = 0.008). Plasma MMP-9 was higher at point III of analysis than at point II. The levels of TIMP-2 increased in following points of the study We did not found the influence of immunophenotype, initial LDH levels and leukocytosis on MMPs and TIMPs values. At diagnosis, the ratio MMP-2/TIMP-1 was at the same level as in the control but it was higher during and after the intensive treatment. At diagnosis as well as during the treatment the ratios MMP-9/TIMP-2 and MMP-9/TIMP-1 were lower than in control. At diagnosis we found a positive correlation between MMP-2 and TIMP-2 (r = 0.679, p = 0.001) and between TIMP-1 and TIMP-2 (r = 0.482, p = 0.027), whereas during the treatment--only a positive correlation between MMP-2 and TIMP-2 was observed (r = 0.766, p = 0.001).


CONCLUSIONS
The differences in plasma matrix metalloproteinases and their tissue inhibitors between leukemic patients and control group, as well as in patients during the treatment, suggest their probable role in the development of leukemic process. The analysis conducted in the bigger group of patients, establishing simultaneously levels of these markers in plasma and in leukemic cells, would be advisable.
Krawczuk-Rybak
Maryna
M
Uniwersytet Medyczny w Białymstoku, Klinika Onkologii i Hematologii Dzieciecej. rybak@umwb.edu.pl
Kuźmicz
Marta
M
Mroczko
Barbara
B
Szmitkowski
Maciej
M
D000293:Adolescent; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood*; D012016:Reference Values; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood*
D015415:Biomarkers; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9